The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma

BACKGROUND: Glioblastoma recurrence after treatment with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is characterized by a highly infiltrative and malignant behavior that renders surgical excision and chemotherapy ineffective. It has been demonstrated that anti-VEGF/VEGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravina, Giovanni Luca, Mancini, Andrea, Marampon, Francesco, Colapietro, Alessandro, Delle Monache, Simona, Sferra, Roberta, Vitale, Flora, Richardson, Peter J., Patient, Lee, Burbidge, Stephen, Festuccia, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217647/
https://www.ncbi.nlm.nih.gov/pubmed/28057017
http://dx.doi.org/10.1186/s13045-016-0377-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217647/
https://www.ncbi.nlm.nih.gov/pubmed/28057017
http://dx.doi.org/10.1186/s13045-016-0377-8

Ejemplares similares